KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aquestive Therapeutics (AQST) Liabilities and Shareholders Equity (2017 - 2026)

Aquestive Therapeutics has reported Liabilities and Shareholders Equity over the past 9 years, most recently at $160.4 million for Q4 2025.

  • For Q4 2025, Liabilities and Shareholders Equity rose 58.17% year-over-year to $160.4 million; the TTM value through Dec 2025 reached $519.9 million, up 13.39%, while the annual FY2025 figure was $160.4 million, 58.17% up from the prior year.
  • Liabilities and Shareholders Equity for Q4 2025 was $160.4 million at Aquestive Therapeutics, down from $163.6 million in the prior quarter.
  • Over five years, Liabilities and Shareholders Equity peaked at $163.6 million in Q3 2025 and troughed at $51.8 million in Q3 2022.
  • A 5-year average of $84.6 million and a median of $63.6 million in 2021 define the central range for Liabilities and Shareholders Equity.
  • Biggest five-year swings in Liabilities and Shareholders Equity: skyrocketed 111.35% in 2024 and later dropped 21.07% in 2025.
  • Year by year, Liabilities and Shareholders Equity stood at $62.0 million in 2021, then dropped by 7.94% to $57.1 million in 2022, then grew by 0.61% to $57.4 million in 2023, then surged by 76.64% to $101.4 million in 2024, then surged by 58.17% to $160.4 million in 2025.
  • Business Quant data shows Liabilities and Shareholders Equity for AQST at $160.4 million in Q4 2025, $163.6 million in Q3 2025, and $93.7 million in Q2 2025.